Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer

被引：1
|
作者：
Scholz, Arne
Knuuttila, Matias
Zdrojewska, Justyna
Suominen, Mari I.
Alhoniemi, Esa
Schatz, Christoph A.
Zitzmann-Kolbe, Sabine
Kakonen, Sanna-Maria
Hagemann, Urs B.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5043
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Synergistic antitumor efficacy of radium-223 in combination with enzalutamide in the intratibial LNCaP prostate cancer xenograft model.
    Suominen, Mari I.
    Knuuttila, Matias
    Vaaraniemi, Jukka
    Sjoholm, Birgitta
    Alhoniemi, Esa
    Mumberg, Dominik
    Kakonen, Sanna-Maria
    Scholz, Arne
    CANCER RESEARCH, 2021, 81 (13)
  • [2] Synergistic antitumor efficacy of radium-223 and enzalutamide in the intratibial LNCaP prostate cancer xenograft model.
    Suominen, Mari, I
    Knuuttila, Matias
    Vaaraniemi, Jukka
    Sjoholm, Birgitta
    Alhoniemi, Esa
    Mumberg, Dominik
    Kakonen, Sanna-Maria
    Scholz, Arne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
    Suominen, Mari I.
    Knuuttila, Matias
    Schatz, Christoph A.
    Schlicker, Andreas
    Vaaraniemi, Jukka
    Sjoholm, Birgitta
    Alhoniemi, Esa
    Haendler, Bernard
    Mumberg, Dominik
    Kakonen, Sanna-Maria
    Scholz, Arne
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [4] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [5] The effects of prednisone, abiraterone acetate and radium-223 dichloride on bone in the intratibial LNCaP prostate cancer model
    Suominen, Mari, I
    Knuuttila, Matias
    Sjoholm, Birgitta
    Alhoniemi, Esa
    Mumberg, Dominik
    Halleen, Jussi M.
    Kaekoenen, Sanna-Maria
    Scholz, Arne
    CANCER RESEARCH, 2020, 80 (16)
  • [6] 177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
    Mateo, Joaquin
    Zurita, Amado J.
    LANCET, 2024, 404 (10459): : 1174 - 1176
  • [7] Antitumor activity of repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Braeuer, Axel
    Yordanova, Anna
    Boegemann, Martin
    Hauser, Stefan
    Eveslage, Maria
    Essler, Markus
    Schafers, Michael
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [8] Myelotoxicity after Treatment with 177Lu-PSMA-617 in Patients with Metastatic Prostate Cancer
    Groener, D.
    Baumgarten, J.
    Davis, K.
    Happel, C.
    Mader, N.
    Ngoc, C. Nguyen
    Wichert, J.
    Mandel, P.
    Tselis, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S694 - S695
  • [9] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [10] Activity of 177Lu-PSMA-617 in Patients With Advanced Prostate Cancer and Brain Metastases
    Rashid, Narmeen S.
    Rami, Avina
    Lang, Min
    Stoltenberg, Hailey
    Wolanski, Andrew
    Ritzer, Jolivette
    Jacene, Heather
    Ravi, Praful
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
12345